

After Your SYNVISIC®/Synvisc-One® (hylan G-F 20) Injection

What to look for:

- Avoid activities that put excessive strain on your knee, such as jogging, lifting, or prolonged standing for 48 hours following the injection. Please consult your doctor regarding the appropriate time to resume such activities
- If you have any mild pain or swelling at the injection site, apply an ice pack on your knee as recommended by your doctor
- The most common side effects seen with the SYNVISIC® family are pain, swelling, heat, redness, and fluid buildup around the knee. Please consult your doctor if you have concerns, if your symptoms do not go away, and/or if you have other side effects

What to expect:

- Everyone responds differently, but many patients experienced osteoarthritis knee pain relief starting 1 month after their Synvisc-One injection¹, or as early as 1 week following the first injection with SYNVISIC²
- SYNVISIC/Synvisc-One can provide up to 6 months of osteoarthritis knee pain relief^{*1,2}



*As shown in a medical studies comparing SYNVISIC® or Synvisc-One® to an injection of salt water.

1. Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. *Ann Rheum Dis.* 2010;69(1):113-119. doi:10.1136/ard.2008.094623.
2. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation with Hylan G-F 20: a 26-week controlled trial of efficacy and safety in the osteoarthritic knee. *Clin Ther.* 1998;20(3):410-423.



Indication

SYNVISIC® (hylan G-F 20) and Synvisc-One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information for Synvisc-One

SYNVISIC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Hypersensitivity reactions including anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and angioedema have been reported for both SYNVISIC and Synvisc-One.

Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because hyaluronan can precipitate in their presence. Do not inject SYNVISIC or Synvisc-One extraarticularly, into the synovial tissues, into the fat pad or joint capsule, or intravascularly.

The safety and efficacy of Synvisc-One in locations other than the knee, or for conditions other than osteoarthritis, or in combination with other intra-articular injectables, or in severely inflamed knee joints have not been established. Use caution when injecting SYNVISIC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of lymphatic or venous stasis in the leg to be treated; or who have severe inflammation in the knee to be treated. Remove any synovial fluid or effusion before injecting SYNVISIC or Synvisc-One. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISIC and Synvisc-One have not been established in children (≤21 years old) or in pregnant or lactating women. Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment after treatment with Synvisc-One.

For SYNVISIC

SYNVISIC® (hylan G-F 20) and Synvisc-One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.

For Synvisc-One

The most commonly reported adverse events were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion. The following reported adverse events are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

Please visit synviscone.com for full Prescribing Information.

Use the appointment reminder to remember when your follow-up appointment is.

SAUS.HYL.18.12.6962 12/18

My Next Appointment

Date:

/

Time:

:

S

M

T

W

Th

F

S

SANOFI

SYNVISIC | SYNVISIC ONE
HYLAN G-F 20 | HYLAN G-F 20